Lyn Baranowski

Chief Executive Officer, Avalyn Pharma

Search every verified Lyn Baranowski interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. Lyn Baranowski, CEO of Avalyn Pharma, discussed the company's work on inhalable medicines for severe lung diseases in a July 2026 podcast appearance. She described Avalyn's approach of reformulating existing oral small molecules into inhaled versions for conditions like pulmonary fibrosis, aiming to deliver drugs more directly to the lungs and potentially improve tolerability over long-term use. Baranowski noted that pulmonary fibrosis has a median survival of 3 to 5 years, which she described as worse than most cancers, and referenced that two oral drugs, pirfenidone and nintedanib, have been approved for the condition in the past decade. She also mentioned that nintedanib, sold as OFEV, is a $4 billion drug, and estimated about 300,000 patients in the US are diagnosed with pulmonary fibrosis annually across its two forms. On her role at Avalyn, Baranowski said she had long admired the company's strategy before joining, and described walking into a situation where she inherited the company with limited financial resources and a mandate from the board to develop a new plan while keeping the same asset focus. She recounted engaging with key opinion leaders and the FDA around inhaled delivery, and observed that patients with these diseases often feel a sense of agency from using inhaled treatments, as it requires more active participation than taking a pill.